Fraud
Big news: Endo begins trading on OTCQX today under the ticker symbol NDOI. Find out more in our press release—including our plans to list on the NYSE later this year: https://lnkd.in/e2B2bYCZ
Skip to main content
Fraud
Big news: Endo begins trading on OTCQX today under the ticker symbol NDOI. Find out more in our press release—including our plans to list on the NYSE later this year: https://lnkd.in/e2B2bYCZ
To view or add a comment, sign in
IPO grants Daiichi patent for Edoxaban orally disintegrating composition. Inventive step & S.3(e) traversed. IN201917022577, family to EP3549585
To view or add a comment, sign in
Lets See on Next Trading Session in AuroPharma Cash (22/11/2023) https://lnkd.in/dArdpQHD Today's High 1058 & Closing LTP @ 1055.75
Positional Call:- Cash stock holding period 6-12 Months Buy Auropharma above 1040 with Stop Loss 976.50 with target 1142.70 - 1245.40 cmp 1027
To view or add a comment, sign in
Non-pharma case: IPO grants patent to Trützschler Group after rejecting Lakshmi Machine' pre-grant opposition. Do read this mechanical domain case on how not to combine documents for lack of inventive step argument. IN201744017840
To view or add a comment, sign in
BioNexus (NASDAQ: BGLC) Stock Surges Amidst Mystery Activity https://lnkd.in/dq2Pwyqj #bionexus #NASDAQ #stockmarketnews #BusinessNews #news #NewsAlert
To view or add a comment, sign in
📊 Dive into the latest insights! Discover how Takeda Pharmaceutical Co. ⚕ surged as the most crowded security (99) in the APAC large-cap category, with Aeon Corp 🏬 taking the lead in institutional supply utilization (21.22%). Uncover more findings and trends in our comprehensive report. Read the full report: https://lnkd.in/e66vJWaR
To view or add a comment, sign in
CTX has the first projects/credits listed (and sold) under the new ICVCM CCP approvals. This represents a microscopic segment of the market, but we have introduced our own Green Tick logo so CTX members do not need to pay for the privilege. These are for sale OTC at a 10% premium. #CarbonMarkets | #CarbonCredits | #ClimateAction
To view or add a comment, sign in
$CARA - Marijuana asset ratings are slipping.: Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States https://lnkd.in/g-d7UgFG #stocks #stocktwits #thematic_portfolio
To view or add a comment, sign in
You're seeing the news on Merck & Co. ($MRK), but did you know it is a holding in $DIVO and $THNR? For complete list of holdings and fund info: Amplify CWP Enhanced Dividend Income ETF https://hubs.li/Q02y_d6p0 Amplify Weight Loss Drug & Treatment ETF https://hubs.li/Q02y_bps0
To view or add a comment, sign in
🚀 Week 16 in Review – OTC Watchlist 🚀 #DUTV #RDGL #BLGO #GGSM #SPZI #SDRC Thank you for joining us as we dive into the highlights from the week. 👀 Keep an eye on this week's top #OTC performers!! #StockMarket #EmergingMarkets #StocksToWatch
To view or add a comment, sign in
Investor with 19 Years' Experience | Join Like-Minded Subscribers for Market Insights & Investing Tips via My Newsletters
Music to an investor’s ears! 🎻 🎶 Biotech company Illumina (ILMN) is being forced to divest from its cancer-testing subsidiary, Grail. ILMN is part of the S&P 500 index. Grail will be too small for the index when it spins off, and all index-tracking funds will be forced to sell the stock! This forced sale has NOTHING to do with the fundamentals of Grail and everything to do with the restrictive mandates of institutional funds. This could present a fantastic opportunity for individual investors and highlights one of the HUGE advantages we have over institutions. I’ll certainly do more research into this! Any of you interested in buying Grail shares? Quote below is from FT article: https://lnkd.in/dZYd3kza #InvestmentOpportunities #IndividualInvestors #GrailSpinoff
To view or add a comment, sign in
Create your free account or sign in to continue your search
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Student at DePaul University
1mo#ShameOnEndo